BCL2L1 and glioblastoma: We recently demonstrated that the loss of PDCD4 in Glioblastoma multiforme (GBM) tumours correlates with an increase in Bcl-xL expression, and that re-expression of PDCD4 results in down-regulated Bcl-xL expression and increased sensitivity to chemotherapeutics [18].